Conception/design: Jingjing Lu, Yang Gu, Lanling Wen. Provision of study materials: Jingjing Lu. Collection and/or extract data: Yang Gu, Jingjing Lu, Qing Li, Huanxin Zhong; Data analysis and statistical guidance: Jingjing Lu, Xiaoxue Wang, Zhenxia Zheng, Wenfeng Hu. Final approval of the manuscript: Lanling Wen.
. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323–37.
. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms’ tumor. Cell 1990;61:1257–69.
. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms’ tumor gene WT1
product. J Immunol 2000;164:1873–80.
. Yang L, Han Y, Saiz FS, et al. A tumor suppressor and oncogene: the WT1
story. Leukemia 2007;21:868–76.
. Coosemans A, Moerman P, Verbist G, et al. Wilms’ tumor gene 1 (WT1
) in endometrial carcinoma. Gynecol Oncol 2008;111:502–8.
. Coosemans A, Nik SA, Caluwaerts S, et al. Upregulation of Wilms’ tumour gene 1 (WT1
) in uterine sarcomas. Eur J Cancer 2007;43:1630–7.
. Hohenstein P, Hastie ND. The many facets of the Wilms’ tumour gene, WT1
. Hum Mol Genet 2006;15:R196–201.
. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004;10:3291–300.
. Rapkiewicz AV, Espina V, Petricoin EF, et al. Biomarkers of ovarian tumours. Eur J Cancer 2004;40:2604–12.
. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis
. Trials 2007;8:16.
. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
. Maxwell L, Santesso N, Tugwell PS, et al. Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol 2006;33:2304–11.
. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–48.
. DerSimonian R, Laird N. Meta-analysis
in clinical trials. Control Clin Trials 1986;7:177–88.
. Thompson SG, Higgins J. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559–73.
. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
. Hylander B, Repasky E, Shrikant P, et al. Expression of Wilms tumor gene (WT1
) in epithelial ovarian cancer. Gynecol Oncol 2006;101:12–7.
. Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, et al. WT1
gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer 2006;6:90.
. Høgdall EV, Christensen L, Kjaer SK, et al. Expression level of Wilms tumor 1 (WT1
) protein has limited prognostic value in epithelial ovarian cancer From the Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol 2007;106:318–24.
. Yamamoto S, Tsuda H, Kita T, et al. Clinicopathological significance of WT1
expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma. Virchows Arch 2007;451:27–35.
. Vermeij R, de Bock GH, Leffers N, et al. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with Wilms tumor protein 1 overexpression. J Immunother 2011;34:516–23.
. Andersson C, Oji Y, Ohlson N, et al. Prognostic significance of specific anti-WT1
IgG antibody level in plasma in patients with ovarian carcinoma. Cancer Med 2014;3:909–18.
. Liu Z, Yamanouchi K, Ohtao T, et al. High levels of Wilms’ tumor 1 (WT1
) expression were associated with aggressive clinical features in ovarian cancer. Anticancer Res 2014;34:2331–40.
. Taube ET, Denkert C, Sehouli J, et al. Wilms tumor protein 1 (WT1
)—not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. Gynecol Oncol 2016;140:494–502.
. Dupont J, Wang X, Marshall DS, et al. Wilms Tumor Gene (WT1
) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray. Gynecol Oncol 2004;94:449–55.
. Ohno S, Dohi S, Ohno Y, et al. Immunohistochemical detection of WT1
protein in endometrial cancer. Anticancer Res 2009;29:1691–5.
. Hedley C, Sriraksa R, Showeil R, et al. The frequency and significance of WT1
expression in serous endometrial carcinoma. Hum Pathol 2014;45:1879–84.
. Coosemans A, Van Calster B, Verbist G, et al. Wilms tumor gene 1 (WT1
) is a prognostic marker in high-grade uterine sarcoma. Int J Gynecol Cancer 2011;21:302–8.
. Sera T, Hiasa Y, Mashiba T, et al. Wilms’ tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis
. Eur J Cancer 2008;44:600–8.
. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1
) in human leukemia. Blood 1997;89:1405–12.
. Loeb DM, Evron E, Patel CB, et al. Wilms’ tumor suppressor gene (WT1
) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001;61:921–5.
. Menssen H, Renkl H, Rodeck U, et al. Presence of Wilms’ tumor gene (wt1
) transcripts and the WT1
nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060–7.
. Nakatsuka S-i, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1
protein in a variety of cancer cells. Mod Pathol 2006;19:804–14.
. Silberstein GB, Van Horn K, Strickland P, et al. Altered expression of the WT1
Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997;94:8132–7.
. Wu C, Zhu W, Qian J, et al. WT1
promotes invasion of NSCLC via suppression of CDH1. J Thorac Oncol 2013;8:1163–9.
. Barbolina MV, Adley BP, Shea LD, et al. Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion. Cancer 2008;112:1632–41.
. Brett A, Pandey S, Fraizer G. The Wilms’ tumor gene (WT1
) regulates E-cadherin expression and migration of prostate cancer cells. Mol Cancer 2013;12:3.
. McCarty G, Awad O, Loeb DM. WT1
protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J Biol Chem 2011;286:43634–43.
. Katuri V, Gerber S, Qiu X, et al. WT1
regulates angiogenesis in Ewing sarcoma. Oncotarget 2014;5:2436–49.
. Gaiger A, Carter L, Greinix H, et al. WT1
-specific serum antibodies in patients with leukemia. Clin Cancer Res 2001;7:761s–5s.
. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1
and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132–7.
. Maheswaran S, Englert C, Bennett P, et al. The WT1
gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 1995;9:2143–56.
. Johnstone RW, See RH, Sells SF, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms’ tumor suppressor WT1
. Mol Cell Biol 1996;16:6945–56.
. Qi X-w, Zhang F, Wu H, et al. Wilms’ tumor 1 (WT1
) expression and prognosis
in solid cancer patients: a systematic review and meta-analysis
. Sci Rep 2015;5:8924.
. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008;27:161–74.